Clinical Trials
Testing the role of thermal jacket in attaining and maintaining Euthermia among preterm and LBW neonates in clinical settings of Bangladesh "
Principal Investigator: Anisuddin AhmedCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 11 Jan, 2024
Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in 6-12 months infant in Bangladesh.
Principal Investigator: Dr Rashidul HaqueCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 27 Dec, 2023
An open label, randomized, laboratory blind single dose two period two treatment two sequence, two-way crossover comparative oral bioavailability study of test product Telmisartan and hydrochlorothiazide (hctz) tablet 80/12.5 mg of Beximco Pharmaceuticals Limited, Bangladesh with reference product Micardis plus 80/12.5 tablet ie Telmisartan and hydrochlorothiazide (hctz) 80/12.5mg of Boehringer Ingelheim PTY Limited, Sydney, Australia in healthy adult male subjects under fasting conditions
Principal Investigator: Dr Uttam K BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 26 Dec, 2023
An open label, randomized, laboratory blind, single dose, two period, two treatment, two sequence, two-way crossover, comparative oral bioavailability study of test product Montelukast Sodium 10 mg tablet of Beximco Pharmaceuticals Limited, Bangladesh with reference product Singulair 10 (Montelukast Sodium 10 mg) Tablet of Organo Pharma PTY Ltd, Australia, in healthy adult human subjects under fasting conditions
Principal Investigator: Dr Uttam K BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 12 Dec, 2023
An open label randomized laboratory blind single dose, two period, two treatment, two sequence, two - way crossover comparative oral bioavailability study of test product Vonoprazan Fumarate 20 mg tablet of Beximco Pharmaceuticals Limited, Bangladesh with reference product Takecab 20 mg tablet I.E Vonoprazan Fumar 20 mg of Takeda Pharmaceutical Company Limited, Japan in healthy adult human subjects under fasting conditions
Principal Investigator: Dr Uttam K BhowmikCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 29 Nov, 2023
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Age De-escalation, Dose Combination Ranging Study to Assess the Safety and Immunogenicity of Co-administered Novel Live Attenuated Trivalent Oral Poliomyelitis Vaccine in Healthy Adults, Young Children, and Neonates and Co-administered Novel Live Attenuated Monovalent Oral Poliomyelitis Vaccines 1 and 2 in Neonates in Bangladesh
Principal Investigator: DR K Zaman Senior Scientist, ICDDRBCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 10 Oct, 2023
IV. A Phase IV open-label, randomized, parallel-group study to evaluate pharyngeal immunity to poliovirus type-2 in healthy bOPV- versus IPV-vaccinated infants
Principal Investigator: Dr K Zaman Senior Scientist ,icddrbCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 2 Oct, 2023
A Randomized, Double-blind, Parallel, Active controlled study to compare the Efficacy and Safety between Ranibizumab 10mg/ml Injection of Incepta Pharmaceuticals Ltd. and Lucentis (Ranibizumab 10mg/ml) of Novartis in patients with Diabetic Macular Edema (DME) by intravitreal injection.
Principal Investigator: Dr Neaz Abdur RahmanCRO: Institute for developing science and health initiatives (ideSHi),
Application Date: 1 Oct, 2023
V. A cluster-randomized, open-label trial to compare the impact of combined Mass Vaccine and Mass Drug administrations, Mass Drug Administration alone, Mass Vaccination alone, and no vaccination or drug administration on Plasmodium falciparum malaria transmission
Principal Investigator: Professor Md Abul FAIzCRO: M/S Dev Care Foundation
Application Date: 13 Sep, 2023
Assessment of a novel fixed-dose combination (fdc) drug VR-AD-1005 for the treatment of acute watery diarrhea in cholera: a phase ii, randomized, placebo-controlled, double-blinded efficacy and safety trial” for your kind evaluation
Principal Investigator: Dr Protim SarkerCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 10 Sep, 2023
Showing 1 to 10 of 65 results
Login with Facebook
Login with Google